Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Pradaxa Quandary: Clearing Both Doses Could Mask Dabigatran's Superiority

Executive Summary

The pivotal issue remaining for FDA's review of Boehringer Ingelheim's Pradaxa (dabigatran) is whether it will clear both the 110 mg and 150 mg doses and how it can craft labeling to guide appropriate use toward the higher dose, which seems likely to gain a superiority claim over warfarin.
Advertisement

Related Content

FDA’s Pradaxa Review Overemphasized Efficacy, Safety Experts Argue
BMJ’s Pradaxa Exposé Includes Wider Call For Monitoring Of All New Anticoagulants
Pradaxa Review Shows FDA Doubts About The Power Of REMS To Change Prescribing Practices
Amid Torrent Of Next-Gen Anticoagulant Data, Trial Design Differences Complicate Comparisons Between Potential Competitors
Amid Torrent Of Next-Gen Anticoagulant Data, Trial Design Differences Complicate Comparisons Between Potential Competitors
FDA Pradaxa Approval Balances Efficacy And Bleeding Risk
Pradaxa Shines On Strength Of Results, But Panelists Wary Of Future Trials With Similar Design
FDA Supports Pradaxa Approval, But Without Superiority Claim
Oral Factor Xa Inhibitors Come Closer To Offering An Alternative To Warfarin
Exanta Superiority To Warfarin Could Reduce Safety Concerns – Cmte.

Topics

Advertisement
UsernamePublicRestriction

Register

PS052647

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel